{
    "ticker": "VKTX",
    "name": "Viking Therapeutics, Inc.",
    "description": "Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Founded in 2012 and headquartered in San Diego, California, Viking Therapeutics is dedicated to improving the lives of patients through innovative drug development. The company leverages its proprietary drug development platform to identify and advance new therapies that target key pathways in metabolic disease. Viking's lead product candidate, VK2809, is an orally administered treatment for non-alcoholic fatty liver disease (NAFLD) and hyperlipidemia, currently in clinical trials. The company also explores other therapeutic areas, including obesity and diabetes, to create a robust pipeline of product candidates. With a commitment to scientific excellence and patient-centric solutions, Viking Therapeutics aims to bring transformative therapies to market that address significant unmet medical needs. The company is actively working to advance its clinical programs and expand its portfolio through rigorous research and strategic partnerships.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2012",
    "website": "https://www.vikingtherapeutics.com",
    "ceo": "Brian Lian",
    "social_media": {
        "twitter": "https://twitter.com/VikingTx",
        "linkedin": "https://www.linkedin.com/company/viking-therapeutics/"
    },
    "investor_relations": "https://ir.vikingtherapeutics.com",
    "key_executives": [
        {
            "name": "Brian Lian",
            "position": "CEO"
        },
        {
            "name": "D. Scott Johnson",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Clinical Candidates",
            "products": [
                "VK2809"
            ]
        }
    ],
    "seo": {
        "meta_title": "Viking Therapeutics, Inc. | Innovative Therapies for Metabolic Disorders",
        "meta_description": "Explore Viking Therapeutics, Inc., a biopharmaceutical company dedicated to developing innovative therapies for metabolic and endocrine disorders. Learn about their clinical candidates and commitment to patient care.",
        "keywords": [
            "Viking Therapeutics",
            "VK2809",
            "Biotechnology",
            "Pharmaceuticals",
            "Metabolic Disorders",
            "Clinical Trials"
        ]
    },
    "faq": [
        {
            "question": "What is Viking Therapeutics known for?",
            "answer": "Viking Therapeutics is known for its development of novel therapies for metabolic and endocrine disorders, particularly its lead candidate VK2809."
        },
        {
            "question": "Who is the CEO of Viking Therapeutics?",
            "answer": "Brian Lian is the CEO of Viking Therapeutics, Inc."
        },
        {
            "question": "Where is Viking Therapeutics headquartered?",
            "answer": "Viking Therapeutics is headquartered in San Diego, California, USA."
        },
        {
            "question": "What are Viking Therapeutics' main products?",
            "answer": "Viking Therapeutics' main product candidate is VK2809, focused on treating NAFLD and hyperlipidemia."
        },
        {
            "question": "When was Viking Therapeutics founded?",
            "answer": "Viking Therapeutics was founded in 2012."
        }
    ],
    "competitors": [
        "AMGN",
        "NVO",
        "SNY"
    ],
    "related_stocks": [
        "JNJ",
        "PFE",
        "MRK",
        "GILD"
    ]
}